Although sorafenib is not the most potent VEGFR TKI against RCC, other VEGFR TKIs that are now parts of first- or second-line regimens also failed to show OS advantage over sorafenib in subsequent lines, despite the superiority in progression-free survival [29]. This evidence concerns the gene KDR and renal cell carcinoma.